Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients

Vaclava Polivkova; Peter Rohon; Hana Klamova; Olga Cerna; Martina Divoka; Nikola Curik; Jan Zach; Martin Novak; Iuri Marinov; Simona Soverini; Edgar Faber; Katerina Machova Polakova

doi:10.1371/journal.pone.0155959

Loading metrics

Open Access

Peer-reviewed

Research Article

Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients

Vaclava Polivkova,

Affiliations Institute of Hematology and Blood Transfusion, Prague, Czech Republic, Faculty of Science, Charles University, Prague, Czech Republic
⨯
Peter Rohon,

Affiliation Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and Faculty Hospital, Olomouc, Czech Republic
⨯
Hana Klamova,

Affiliations Institute of Hematology and Blood Transfusion, Prague, Czech Republic, Institute of Clinical and Experimental Hematology of the 1st Medicine Faculty, Charles University, Prague, Czech Republic
⨯
Olga Cerna,

Affiliation Department of Internal Medicine and Hematology, 3rd Faculty of Medicine and Faculty Hospital Kralovske Vinohrady, Charles University, Prague, Czech Republic
⨯
Martina Divoka,

Affiliation Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and Faculty Hospital, Olomouc, Czech Republic
⨯
Nikola Curik,

Affiliation Institute of Hematology and Blood Transfusion, Prague, Czech Republic
⨯
Jan Zach,

Affiliation Institute of Hematology and Blood Transfusion, Prague, Czech Republic
⨯
Martin Novak,

Affiliation Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and Faculty Hospital, Olomouc, Czech Republic
⨯
Iuri Marinov,

Affiliation Institute of Hematology and Blood Transfusion, Prague, Czech Republic
⨯
Simona Soverini,

Affiliation Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy
⨯
Edgar Faber ,

¶‡ These authors are co-senior authors on this work.

Affiliation Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and Faculty Hospital, Olomouc, Czech Republic
⨯
Katerina Machova Polakova

* E-mail: katerina.machova@uhkt.cz

¶‡ These authors are co-senior authors on this work.

Affiliations Institute of Hematology and Blood Transfusion, Prague, Czech Republic, Institute of Clinical and Experimental Hematology of the 1st Medicine Faculty, Charles University, Prague, Czech Republic
⨯

Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients

Vaclava Polivkova,
Peter Rohon,
Hana Klamova,
Olga Cerna,
Martina Divoka,
Nikola Curik,
Jan Zach,
Martin Novak,
Iuri Marinov,
Simona Soverini

Published: May 23, 2016
https://doi.org/10.1371/journal.pone.0155959

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Cloning
Is the Subject Area "Cloning" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Stem cell therapy
Is the Subject Area "Stem cell therapy" applicable to this article?

Thanks for your feedback.
T cells
Is the Subject Area "T cells" applicable to this article?

Thanks for your feedback.
NK cells
Is the Subject Area "NK cells" applicable to this article?

Thanks for your feedback.
Immune response
Is the Subject Area "Immune response" applicable to this article?

Thanks for your feedback.
Medical risk factors
Is the Subject Area "Medical risk factors" applicable to this article?

Thanks for your feedback.
Point mutation
Is the Subject Area "Point mutation" applicable to this article?

Thanks for your feedback.